Objective: The purpose of this study was to evaluate the impact of preoperative inflammatory status, as determined by complete blood count test parameters, on 12-and 24-month patency of femoropopliteal stenting for peripheral arterial disease.
Results: Univariate analysis determined that the 81 patients (59%) who experienced ISR within 12 months had significantly higher preoperative white blood cell (WBC), platelet, neutrophil, and lymphocyte counts than the 57 patients (41%) whose stents remained patent for longer than 12 months (8.7 vs 6.7 [P < .001], 246 vs 184 [P < .001], 5.7 vs 4.7 [P ¼ .001], and 1.8 vs 1.2 [P ¼ .004], respectively). Compared with patients in the lower WBC tertile (n ¼ 45) who had a median patency of 19.4 months, those in the upper WBC tertile (n ¼ 44) had a median patency of only 7.0 months and a 3.3-fold increased risk for ISR after adjusting for age, sex, lesion type, TransAtlantic Inter-Society Consensus II score, tibial vessel runoff, antiplatelet therapy, presence of diabetes, critical limb ischemia, adjunct procedures, hyperlipidemia, and end-stage renal disease in multivariate analysis (P < .001). Compared with patients in the lower platelet tertile (n ¼ 45) who had a median patency of 16.9 months, those in the upper platelet tertile (n ¼ 47) had a median patency of 7.1 months and a 2.7-fold increased adjusted risk (P ¼ .001). Compared with patients in the lower neutrophil tertile (n ¼ 33) who had a median patency of 14.3 months, those in the upper neutrophil tertile (n ¼ 33) had a median patency of 6.2 months and a 3.2-fold increased adjusted risk (P ¼ .001). After adjusting for covariates, patients divided into tertiles by lymphocyte counts exhibited no significant differences for ISR.
Conclusions: Routine preoperative tests that determine baseline inflammatory status may provide strong clinical utility in assessing potential risk stratification of patients for ISR after femoropopliteal stenting. Circulating WBCs, platelets, and neutrophils may be important inflammatory mediators of ISR. (J Vasc Surg 2017; 66:151-9.) Peripheral arterial disease (PAD) is a widespread vascular problem of significant consequence, affecting >8.5 million Americans older than 40 years and contributing to claudication and critical limb ischemia. 1 Throughout the years, endovascular revascularization through stenting has emerged as a common primary procedure for treating infrainguinal PAD. However, neointimal hyperplasia leading to in-stent restenosis (ISR) continues to be a major limitation that prevents longterm patency. Loss of primary patency from ISR after superficial femoral artery stenting has been documented as high as 47% within 12 months. 2 Subsequently, ISR often requires secondary endovascular or open surgical reinterventions, adding to the burden of patients with PAD. Identifying key mediators involved in the pathophysiologic mechanism of ISR is crucial for guiding decision-making in the management of PAD and improving the long-term patency of peripheral stents. Although ISR is a complex and multifactorial process, there is well-established evidence that inflammation plays a critical role in contributing to neointimal hyperplasia. Several studies from the coronary artery literature have indeed demonstrated associations between inflammatory biomarkers and ISR, suggesting that certain patients may be predisposed to higher risk of restenosis on the basis of simple hematologic parameters. [3] [4] [5] 
METHODS
Study design. We conducted a retrospective assessment of clinical and angiographic records from January 2005 to October 2014 of all patients who underwent first-time stenting of femoral or above-the-knee popliteal arterial occlusive disease at the Mount Sinai Hospital (New York). Our study population included only patients with available preoperative CBC test results and information of patency for at least 12 months after operation. Patients with a history of prior interventions for lower limb revascularization, cancer, human immunodeficiency virus infection, transplants, or other autoimmune diseases were excluded. Subjects were also excluded if they experienced any other recent significant medical events (ie, myocardial infarction, stroke, major surgical procedure, or active infection) within 30 days before the index operation. Information about patient demographics, PAD risk factors, comorbid conditions, procedural characteristics, and discharge medications was noted and systematically reviewed from the patients' electronic hospital records. Diagnoses of comorbid conditions, such as hyperlipidemia and diabetes, were recorded if they were clearly noted in the charts, instead of examining actual cholesterol, glucose, and hemoglobin A 1c levels. Institutional Review Board approval was obtained for this study and conducted in accordance with the Health Insurance Portability and Accountability Act and the prevailing ethical principles governing research. Informed consent of the patient was waived.
Hematologic parameters. Patients can receive either a simple CBC or CBC with differential. The CBC provides absolute white blood cell (WBC), red blood cell, and platelet counts as well as mean platelet volume, hemoglobin concentration, hematocrit, mean corpuscular volume, and red cell distribution width. The CBC with differential also records additional information about neutrophil, lymphocyte, monocyte, eosinophil, and basophil counts.
For this study, the first preoperative CBC test recorded on admission was used to determine the patient's baseline inflammatory status. If a preoperative CBC test was not performed during admission, we used the most recent CBC within 30 days before intervention. All CBC tests were conducted at our institution within a few hours after initial blood sample collection using a Coulter LH755 or LH785 automated machine with SlideMaker and SlideStainer (Beckman Coulter Inc, Brea, Calif).
Interventions. Experienced vascular interventionalists (vascular surgeons or interventional radiologists) performed all procedures using fixed fluoroscopic equipment (Siemens, Munich, Germany) or a portable imaging fluoroscopic C-arm (OEC 9800; GE Medical Systems, Milwaukee, Wisc), following standard techniques as previously described. 6, 7 Computed tomography angiography, hemodynamic studies, or digital subtraction angiography was used to preoperatively evaluate lesion severity and anatomy. Lesions were classified as chronic total occlusions or stenotic (50%-99% stenosis) and were further categorized according to TransAtlantic Inter-Society Consensus II (TASC II) classification. 8 Angioplasty with a non-drug-coated balloon was uniformly performed, and if there was >30% residual stenosis or flow-limiting dissection, a self-expanding nitinol stent was deployed. None of the patients in this series received drug-eluting stents, covered stents, or adjunct atherectomy. Stent dimensions were chosen at the discretion of the interventionist. Completion angiography was performed to determine patency and tibial vessel runoff. Primary technical success was defined as a residual stenosis of <30% within the stent according to the final angiogram. All patients were discharged on aspirin (81 or 325 mg), clopidogrel (300 to 450 mg given immediately after intervention with maintenance dose of 75 mg for at least 30 days), or both antiplatelet medications.
Study end point. The primary study end point was ISR within 24 months after the procedure. ISR, which was considered loss of primary patency, was defined by a peak systolic velocity ratio $2.5:1 within the stent or computed tomography angiography demonstrating $50% in-stent luminal narrowing. Peak systolic velocity was determined by duplex ultrasound with color Doppler interrogation performed at routine follow-ups at a minimum of 3, 6, 9, 12, and 24 months postoperatively. uous variables, such as CBC test parameters, were presented as median with interquartile range (IQR; 25th and 75th percentiles) and compared using a Mann-Whitney U test. Similar to other prior studies, Kaplan-Meier survival analysis with log-rank test was used to compare ISR rate differences during a 24-month period among hematologic parameters categorized in tertiles (33rd and 67th percentiles). 4, 5, 9, 10 Finally, multivariate Cox regression analysis adjusting for characteristics of the patients, comorbid conditions, symptoms, lesion characteristics, and runoff was performed to determine adjusted hazard ratios and to identify independent predictors of ISR. For all analyses, P # .05 was considered statistically significant. Statistical calculations were completed using SPSS for Mac (version 23.0; IBM Corp, Armonk, NY).
RESULTS
From 2005 to 2014, there were 479 unique patients who underwent first-time femoropopliteal stenting by the authors without any prior interventions for lower limb Congestive heart failure 28 (20) 14 (25) 14 (17) .30
Chronic occlusive pulmonary disease 12 (9) 5 (9) 7 (9) .98
End-stage renal disease 8 (6) 5 (9) (Table I) . Before intervention, 55% of femoropopliteal lesions were chronic total occlusions; the remaining had 50% to 99% stenosis. The majority of patients had lesions morphologically categorized as TASC type B (66%) compared with 8% having type A, 20% having type C, and 6% having type D; 46%, 29%, and 25% had one-, two-, and three-vessel runoff, respectively.
The median stent length was 150 mm, and all of the stents achieved primary technical success; 29% of patients required adjunct, concomitant interventions (angioplasty or stenting) for additional iliac or tibial lesions. On discharge, all patients were prescribed antiplatelet therapy, with the majority receiving both aspirin and clopidogrel (62%); 9% received only aspirin and 29% received only clopidogrel. Other commonly prescribed discharge medications included angiotensin-converting enzyme inhibitors (40%), beta blockers (61%), and statins (66%; Table I ). None of the patients were receiving any immunosuppressive therapy.
The overall 24-month primary patency rate of the femoropopliteal stents was 21% with a median follow-up time of 22 months; 81 patients (59%) had ISR within 12 months compared with 57 patients (41%) whose stents remained patient for longer than 12 months. Comparing the two cohorts, the patients in the ISR group were more likely to be diabetic (P ¼ .028) and tended to be younger (68 vs 75 years; P ¼ .051), female (P ¼ .080), and hyperlipidemic (P ¼ .060) and to require adjunct tibial or iliac interventions (P ¼ .090). There were no other significant differences in demographics of the patients, risk factors, comorbid conditions, procedural characteristics, and discharge medications (all P > .050; Table I ). Patients who had ISR within 12 months had significantly higher preoperative WBC (8.7 vs 6.7), neutrophil (5.7 vs 4.7), lymphocyte (1.8 vs 1.2), and platelet (246 vs 184) counts than those whose stents remained patent for >12 months (P < .05; Table II) . No significant differences were found regarding other baseline hematologic values (Table II) .
Patients were then stratified into tertiles on the basis of preoperative WBC, platelet, neutrophil, and lymphocyte counts to evaluate their associations with ISR during 24 months (Fig) . The final multivariate Cox proportional hazards model adjusted for age, sex, lesion type (chronic total occlusion vs 50%-99% stenosis), TASC II score, tibial vessel runoff, antiplatelet therapy, diabetes, hyperlipidemia, and end-stage renal disease.
The lower WBC tertile consisted of patients with WBC counts <6.8 (n ¼ 45); the middle WBC tertile, with counts between 6.8 and 9.1 (n ¼ 49); and the upper WBC tertile, with counts >9.1 (n ¼ 45). The median patency was 19, 8, and 7 months, respectively, and the numbers of patients with patent stents after 24 months were 13 (29%), 12 (24%), and 4 (9%), respectively (Fig; Table III Patients with platelet counts <184 were grouped in the lower platelet tertile (n ¼ 45); counts between 184 and 257, in the middle platelet tertile (n ¼ 47); and counts >257, in the upper platelet tertile (n ¼ 46). The median patency was, respectively, 17, 10, and 7 months. The lower platelet tertile had 15 patients (33%) with patent stents after 24 months; the middle and upper tertiles had 11 (23%) and 3 (7%), respectively (Fig; Table III) . The unadjusted hazard ratio for ISR, relative to the lower platelet tertile, was 1.8 for the middle tertile (95% CI, 1.0-3.3; P ¼ .046) and 2.7 for the upper tertile (95% CI, 1.5-4.8; P < .001; Table III ). After adjusting for covariates, the middle tertile compared with the lower tertile had a 1.8-increased risk for ISR (95% CI, 1.0-3.3; P ¼ .046). The upper tertile had a 2.7-fold increased adjusted risk (95% CI, 1.5-4.8; P ¼ .001; Table III ).
The lower neutrophil tertile (counts <4.5; n ¼ 33) had a median patency of 14 months, with 10 patients (30%) having patent stents after 24 months. The middle neutrophil tertile (counts between 4.5 and 5.8; n ¼ 30) had a median patency of 13 months, with nine patients (30%) having patent stents after 24 months. Finally, the upper neutrophil tertile (counts >5.8; n ¼ 33) had a median patency of 6 months, with two patients (6%) having patent stents after 24 months (Fig; Table III) . Compared with the lower neutrophil tertile, the unadjusted and adjusted hazard ratios of the upper neutrophil tertile were 3.1 (95% CI, 1.8-5.6; P < .001) and 3.2 (95% CI, 1.6-6.4; P ¼ .001), respectively (Table III) . No significant differences were seen between middle and lower neutrophil tertiles (Table III) .
Patients with lymphocyte counts <1.2, between 1.2 and 1.9, and >1.9 were divided in lower, middle, and upper lymphocyte tertiles, respectively. The lower lymphocyte tertile (n ¼ 27) had a median patency of 17 months, among which seven patients (26%) had patent stents after 24 months. The middle lymphocyte tertile (n ¼ 36) had a median patency of 10 months, among which nine patients (25%) had patent stents after 24 months. The upper lymphocyte tertile (n ¼ 33) had a median patency of 7 months, among which five patients (15%) had patent stents after 24 months (Fig; Table III) . The upper lymphocyte tertile had a 2.4-increased unadjusted risk for ISR compared with the lower tertile (95% CI, 1.1-5.0; P ¼ .021), but after adjusting for covariates, the difference was no longer significant (P ¼ .06; Table III ). There were no significant differences in unadjusted or adjusted risks between middle and lower lymphocyte tertiles (Table III) . Among the covariates included in the final multivariate Cox proportional hazards model, only hyperlipidemia emerged as an independent risk factor for ISR when patients were stratified into tertiles on the basis of WBC, platelet, neutrophil, or lymphocyte counts (P ¼ .047, not shown).
DISCUSSION
Identifying which patients with PAD will respond optimally to stenting or other percutaneous interventions is of paramount importance for improving outcomes and using resources efficiently. This study has assessed the prognostic value of using inflammatory and hematologic parameters in predicting primary patency of femoropopliteal stents. In summary, elevated preoperative WBC, platelet, and neutrophil counts may be strong, independent predictors of ISR after femoropopliteal stenting.
Over the years, managing femoropopliteal disease has remained challenging for vascular surgeons. In this decade-long study from 2005 to 2014, we report overall primary patency rates (6-, 12-, and 24-month: 71%, 41%, and 21%, respectively) that are lower than those reported in several well-known randomized controlled trials using self-expanding nitinol stents. 2, [11] [12] [13] [14] Compared with these trials, our studied cohort had longer and more complex lesions, as evidenced by an overall median stent length were classified as TASC C or D, 55% had total occlusions, 46% had one tibial vessel runoff, and 29% required adjunct iliac or tibial interventions. 11, 12, 14 In addition, a significantly higher percentage of patients had diabetes (67%) and critical limb ischemia (76%) compared with the trials. Surprisingly, none of these parameters were determined to be independent predictors of ISR in our study. Instead, the lesion characteristics described in this study were more comparable to those in the recent Study to Treat Superficial Femoral Artery Occlusions (SUPER) trial, which investigated long superficial femoral artery lesions with average length of 120 mm and 95% total occlusions. 2 Primary patency in the SUPER trial was 53%, which is closer to the 41% 12-month primary patency in this series. 2 There are other important factors that could affect differences in reported patency rates, such as minor differences in study end point criteria and follow-up intervals as well as the decade-long span of this study, which likely included earlier-generation stents. Moreover, at our institution, we offer to first attempt angioplasty with or without stenting regardless of lesion criteria before considering open surgery bypass or any other intervention. The use of provisional stenting could have affected our overall patency as these lesions could be argued to be more challenging to treat. This strategy has been implemented throughout the years, but our most recent results highlight the need for better risk stratification of patients for optimal vascular management. Whereas the exact mechanisms of ISR remain under ongoing investigation, many believe leukocyte-platelet interactions are critical in promoting ISR.
3,15-17 Welt and Rogers proposed that after stent-induced direct arterial wall injury, a layer of activated platelets and fibrinogen is deposited at the injured site, signaling the initial margination and rolling process. Circulating leukocytes that express leukocyte b 2 integrin Mac-1 (CD11/18), such as neutrophils, then bind directly to platelet receptors, notably glycoprotein Iba. [18] [19] [20] Finally, migration across the platelet-fibrin layer into the vascular tissue is triggered by chemokines produced by smooth muscle cells and resident macrophages. 3, 15 Over time, cytokines and growth factors from platelets, leukocytes, and smooth muscle cells result in proliferative hyperplastic remodeling that can ultimately cause ISR. 3 Our findings suggest that rather than active ongoing inflammation, elevated baseline WBC, platelet, and neutrophil counts may represent a hyper-responsive predisposition to the acute inflammatory stimulus of stenting. To our knowledge, Schillinger et al conducted the only other study that investigated the relationship between preoperative inflammatory cell counts and femoropopliteal ISR during a 24-month period. 9 Their cohort of patients differed greatly from ours as only 27% had critical limb ischemia, and the median length of implanted stents was 70 mm. Remarkably, the overall 6-and 12-month patency rates (70% and 41%) were nearly identical to those found in our study (71% and 41%), indicating that ISR can commonly occur within the first few months after intervention. 9 Of note, a separate study that investigated carotid artery stenting determined that the majority of ISR occurred within the first year, further suggesting the acute nature of the restenotic process. 21 Interestingly, Schillinger et al found no correlations for neutrophils, which was acknowledged as surprising because of their known involvement in ISR. 9 They also determined a strong relationship between increased monocytes and ISR, which our study did not demonstrate. Our cohort may have lacked the power to defect a significant effect of monocytes, given the low variability in monocyte counts (IQR, 0.5-0.8) compared with neutrophil levels (IQR, 3.9-7.3). Information concerning baseline inflammatory status and ISR primarily derives from the coronary literature as pre-existing systemic inflammation has been well known to correlate with future adverse cardiovascular events. For instance, patients with the highest WBC, neutrophil, and monocyte counts, respectively, had a 1.4-fold, 1.8-fold, and 1.3-fold increased adjusted risk for myocardial infarction or death compared with those with the lowest leukocyte counts. 22 On the contrary, several studies have identified a negative predictive role of lymphocyte counts in cardiac patients with coronary artery disease, unstable angina, and advanced heart failure. [23] [24] [25] [26] [27] Turak et al determined that patients with stable or unstable angina stratified in the highest preoperative neutrophil to lymphocyte (N/L) tertile had a 51.4% ISR rate after coronary artery stenting compared with 10.1% among the lowest tertile (P < .001), whereas Yilmaz et al also showed that elevated preoperative platelet to lymphocyte (P/L) ratios were significantly associated with ISR (upper vs lower tertile, 51% and 29%, respectively; P < .001). 4, 5 High preoperative N/L and P/L ratios have similarly been found to be independent predictors of mortality after coronary artery stenting. 10, 23 Because of a lack of strong existing evidence, it remains unclear why decreased lymphocytes, as implied by high N/L and P/L ratios, would paradoxically seem to promote worse outcomes, including ISR. In our study, elevated lymphocyte counts were instead associated with ISR at 12 months but exhibited no statistical significance during 24 months after adjusting for covariates. Nevertheless, although we did not find any significant associations regarding N/L and P/L ratios, these previous observations do suggest decreased patency with elevated levels of circulating neutrophils and platelets, which is consistent with our results. Similar conclusions have been made with regard to patency of vein grafts, despite major differences in operational technique from percutaneous stenting. WBCs and platelets, in particular, have been implicated in the narrowing and failure of both coronary and infrainguinal vein grafts. 28, 29 Baseline systemic inflammation as reflected by serum C-reactive protein (CRP) concentration also appears to influence the early shear-dependent response of lower extremity vein graft remodeling and has thus been proposed as a therapeutic target of vein adaptation. 30 Together with our results, it seems that priority should be given to resolving elevated preoperative inflammatory levels to optimize outcomes, regardless of the type of revascularization procedure. Interestingly, Hiramoto et al found that women undergoing lower extremity bypass with autogenous vein had significantly higher baseline CRP concentration than men, and only women with elevated CRP levels were associated with lower patency of vein grafts. 31 Whereas female patients in our study cohort were not independently associated with higher rates of ISR, separate analysis determined that they tended to present with slightly higher baseline WBC, platelet, and neutrophil counts than male patients (P < .08, not shown). Additional considerations for possible differences in inflammatory profiles between the sexes may need to be taken into account for future perioperative surveillance protocols. Of note, there are several limitations inherent to the retrospective nature of this single-institution study. Information about additional nonspecific inflammatory markers, such as serum CRP and erythrocyte sedimentation rate, was largely unavailable. Also, a number of patients received only CBCs without differentials, giving us no information about their neutrophil or lymphocyte counts. Previously, there was no standardized protocol for receiving a preoperative CBC vs CBC with differential before stenting. Furthermore, our cohort of patients did not have cancer, human immunodeficiency virus infection, transplants, autoimmune diseases, or any significant medical events (ie, myocardial infarction, major surgical procedure, or active infection) within 30 days before operation, and hence there was likely no clear indication for one test over the other. As expected, there were no significant differences in hematologic parameters among patients who received a CBC vs CBC with differential, reducing the likelihood of selection bias and allowing us to analyze the patients together. In addition, it may be the case that analysis of multiple blood samples that also span the postoperative period better represents baseline inflammatory status than a single preoperative surrogate marker. Postoperative CBCs were mostly unavailable but would be valuable in determining whether inflammatory levels change with time, leading up to ISR. Finally, despite controlling for many covariates, there may have been other confounding variables that were not accounted for in our multivariate analysis. For instance, antiplatelet therapy and other medications were noted on discharge, but we did not adjust for the patient's adherence to these medications, which may have been an important confounding factor. Future studies may consider correcting for medication adherence in determining how it may influence longterm patency of stents.
Nonetheless, our study has shown that simple hematologic parameters can potentially provide useful information in predicting the long-term patency of femoropopliteal stents. These results further highlight the possible impact that high circulating WBC, platelet, and neutrophil levels can have on future ISR. Additional studies are necessary to establish clinically applicable cutoff levels instead of "normal" reference ranges for accurate risk stratification of vascular patients and whether those patients with the highest risk for ISR are better indicated for alternative medical or surgical management. Questions certainly remain as to whether reducing these inflammatory mediators before stenting can actually prolong stent patency. Controlled, randomized, prospective studies that investigate the effect of statins, steroids, nonsteroidal anti-inflammatory drugs, and other novel immunotherapies on ISR are warranted. Finally, the clinical utility of baseline inflammatory markers should be re-examined in light of new drugeluting stents.
CONCLUSIONS
Baseline hematologic tests may provide clinical utility in risk stratifying vascular patients and optimizing care with regard to PAD revascularization. More specifically, our study showed that the patency of femoropopliteal stents is strongly associated with elevated preoperative WBC, platelet, and neutrophil counts. Overall, these findings support the hypothesis that the pathophysiologic mechanism of ISR involves acute inflammatory processes driven by circulating platelets and neutrophils. Future studies are necessary to establish whether treatments aimed at reducing baseline inflammatory levels can be effective in preventing ISR. 
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